Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2001
10/04/2001WO2001072765A1 ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING
10/04/2001WO2001072762A1 Pharmaceutical compositions containing oligosaccharides and preparation thereof
10/04/2001WO2001072758A1 Tricyclic protein kinase inhibitors
10/04/2001WO2001072757A1 Tricyclic imidazopyridines
10/04/2001WO2001072756A1 Prodrugs of imidazopyridine derivatives
10/04/2001WO2001072755A1 Pyrano[2,3-c]imidazo[-1,2-a]pyridine derivatives for the treatment of gastrointestinal disorders
10/04/2001WO2001072754A1 Alkylated imidazopyridine derivatives
10/04/2001WO2001072752A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-a]INDOLE COMPOUNDS
10/04/2001WO2001072749A1 Condensed pyrazole derivatives, process for producing the same and use thereof
10/04/2001WO2001072747A1 Crystalline form ii of cabergoline
10/04/2001WO2001072746A1 Crystalline form vii of cabergoline
10/04/2001WO2001072745A1 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders
10/04/2001WO2001072744A1 N-heterocyclic derivatives as nos inhibitors
10/04/2001WO2001072738A1 Quinolonecarboxylic acid derivative
10/04/2001WO2001072737A1 Triarylimidazole derivatives as cytokine inhibitors
10/04/2001WO2001072733A1 Derivatives of p- hydroxy phenyl propionic acid as antiproliferative agents
10/04/2001WO2001072730A1 Selective preventives/remedies for progressive lesions after organ damage
10/04/2001WO2001072728A2 Novel piperazine derivatives
10/04/2001WO2001072727A1 Hair tonics
10/04/2001WO2001072723A1 Oxa(thia)zolidine derivative and anti-inflammatory drug
10/04/2001WO2001072721A2 Synergistic methods and compositions for treating cancer
10/04/2001WO2001072720A1 Bicyclic amine derivatives as inhibitors of class 1 receptor tyrosine kinases
10/04/2001WO2001072718A1 Pharmaceutical compositions containing as the active ingredient nitropyrimidine derivatives or salts thereof
10/04/2001WO2001072717A1 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
10/04/2001WO2001072714A2 Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker
10/04/2001WO2001072713A1 Non-steroidal, tetracyclic compounds for estrogen-related treatments
10/04/2001WO2001072711A1 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
10/04/2001WO2001072709A1 Naphtalene derivatives and their pharmaceutical use
10/04/2001WO2001072707A2 Carbamate caspase inhibitors and uses thereof
10/04/2001WO2001072705A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors
10/04/2001WO2001072703A1 Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
10/04/2001WO2001072702A2 Amidino compounds useful as nitric oxide synthase inhibitors
10/04/2001WO2001072701A1 Ceramide derivatives and method of use
10/04/2001WO2001072699A1 Inhibition of angiogenesis and tumor growth
10/04/2001WO2001072694A1 Zofimarin derivatives
10/04/2001WO2001072692A1 Malonamic acids and derivatives thereof as thyroid receptor ligands
10/04/2001WO2001072687A1 Diphenyl ether compounds useful in therapy
10/04/2001WO2001072685A2 Polyamine analogues as cytotoxic agents
10/04/2001WO2001072680A1 Substituted chalcones as therapeutic compounds
10/04/2001WO2001072678A1 Phenol derivatives, process for preparation of the same and use thereof
10/04/2001WO2001072669A2 Therapeutic use of polyhydroxy amine derivates
10/04/2001WO2001072347A1 Agents promoting the formation of skin basement membrane, agents promoting the formation of artificial skin and process for producing artificial skin
10/04/2001WO2001072341A2 Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation
10/04/2001WO2001072335A2 Methods for effecting neuroprotection using a potassium channel modulator
10/04/2001WO2001072319A1 Tea catechin formulations and processes for making same
10/04/2001WO2001072318A1 Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
10/04/2001WO2001072315A1 Emulsion containing a plant extract, method for producing said emulsion and for obtaining a plant extract
10/04/2001WO2001072311A1 Inhibition of a novel calcium injury current that forms in neurons during injury prevents neuronal cell death
10/04/2001WO2001072310A1 Pharmaceutical gel composition
10/04/2001WO2001072309A2 Treatment of cerebrovascular disease
10/04/2001WO2001072308A1 Composition and method for intervening neuronal death using sulfasalazine
10/04/2001WO2001072307A1 Methods of treating cognitive decline disease conditions with androgens
10/04/2001WO2001072306A1 Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system
10/04/2001WO2001072305A1 A medicament and method for the production thereof
10/04/2001WO2001072304A1 A novel anti-microbial composition and method for producing the same
10/04/2001WO2001072302A1 Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists
10/04/2001WO2001072301A1 Intracorporeal medicaments for photodynamic treatment of disease
10/04/2001WO2001072300A1 Uses of metal salts to stabilize taxane-based compositions
10/04/2001WO2001072299A1 Taxane-based compositions and methods of use
10/04/2001WO2001072298A1 Treatments for immune-mediated ear disorders
10/04/2001WO2001072297A1 Methods for inhibiting angiogenesis and tumor growth
10/04/2001WO2001072296A1 Method of inhibiting the expression of inflammatory cytokines and chemokines
10/04/2001WO2001072294A2 Method of treating hepatitis delta viral infection
10/04/2001WO2001072293A2 Antiprogestins with partial agonist activity
10/04/2001WO2001072292A2 Vitamin d compounds used to stabilize kidney transplants
10/04/2001WO2001072291A2 Treatment of movement disorders with metabotropic glutamate receptor antagonist
10/04/2001WO2001072290A2 Method for the improvement of islet signaling in diabetes mellitus and for its prevention
10/04/2001WO2001072288A2 Use of cdp-choline for the treatment of alcohol withdrawal syndrome
10/04/2001WO2001072287A2 Use of ectoin or ectoin derivatives for the prophylaxis and/or treatment of uv-induced immunosuppression
10/04/2001WO2001072283A1 Cationic liposomes
10/04/2001WO2001072281A2 Microspheres for active embolization
10/04/2001WO2001072279A2 Medical emulsion for lubrication and delivery of drugs
10/04/2001WO2001072268A1 Hair growth or hair formation controlling agents
10/04/2001WO2001072264A2 Pro-liposomal encapsulated preparations (iv)
10/04/2001WO2001072136A1 Sterol ester compositions
10/04/2001WO2001072124A1 Bacterial growth regulators or inhibitors with the use of 1,5-d-anhydrofructose
10/04/2001WO2001049688A8 Purine derivatives, process for their preparation and use thereof
10/04/2001WO2001047878A8 Substituted pyrrole mannich bases to combat pain and allergic reactions
10/04/2001WO2001046144A8 New modulators of dopamine neurotransmission
10/04/2001WO2001044198A8 Amphiphilic quinolylpolyamines as transfer agents for biologically active macromolecules
10/04/2001WO2001043704A8 A skin care composition that mediates cell to cell communication
10/04/2001WO2001034565A3 Protease inhibitors
10/04/2001WO2001032685A3 Gene expression directed by a super-psa promoter
10/04/2001WO2001028499A3 A therapeutic mixture of hmg-coa reductase inhibitors
10/04/2001WO2001024780A3 Soft gel capsule resistant to gastric juices
10/04/2001WO2001022990A3 Methods related to immunostimulatory nucleic acid-induced interferon
10/04/2001WO2001022959A3 Compositions comprising progesterone or progesterone analogs for the treatment of inflammatory conditions
10/04/2001WO2001019832A3 Thienoisoxazole phenoxy unsubstituted ethyl and propyl derivatives useful as d4 antagonists
10/04/2001WO2001019828A3 Kinase inhibitors as therapeutic agents
10/04/2001WO2001019373A3 Methods and compositions for modulating responsiveness to corticosteroids
10/04/2001WO2001019361A3 Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate
10/04/2001WO2001019358A3 Use dexrazoxane for treating psoriasis
10/04/2001WO2001019322A3 Use of csaids in rhinovirus infection
10/04/2001WO2001019321A3 Methods for treating neuropathic pain using hetreoarylmethanesulfonamides
10/04/2001WO2001013957A3 Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
10/04/2001WO2001012838A3 Compounds which modulate the activity of an lpa receptor
10/04/2001WO2001012214A3 MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a)
10/04/2001WO2001005764A3 Sulfuric acid mono-[3-({1- [2-(4-fluoro-phenyl)-ethyl]- piperidin-4-yl}- hydroxy- methyl)-2- methoxy-phenyl]ester
10/04/2001WO2001000663A3 Catalytically active recombinant memapsin and methods of use thereof
10/04/2001WO2000078343A8 Method for treating chronic hbv infection
1 ... 6001 6002 6003 6004 6005 6006 6007 6008 6009 6010 6011 6012 6013 6014 6015 6016 6017 6018 6019 6020 6021 ... 7860